The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A ten-membered synthetic oligopeptide consisting of D-Arg, Arg, Pro, Hyp, Gly, Thi, Ser, D-Tic, Oic, and Arg residues joined in sequrence. A bradykinin receptor antagonist used as its acetate salt for the treatment of acute attacks of hereditary angioedema in adult patients.
icatibant binds to and results in decreased activity of BDKRB2 protein; icatibant inhibits the reaction [FR 190997 binds to and results in increased activity of BDKRB2 protein]; icatibant inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Chondroitin Sulfates; [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Streptozocin; [icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Vincristine; [icatibant results in decreased activity of BDKRB2 protein] inhibits the reaction [Valsartan results in increased abundance of Cyclic GMP]; [icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to benazepril; [icatibant results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Valsartan; icatibant binds to and results in decreased activity of BDKRB2 protein; icatibant inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates] icatibant binds to and results in decreased activity of BDKRB2 protein; icatibant inhibits the reaction [KNG1 protein modified form binds to BDKRB2 protein]
icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased expression of ICAM1 protein]]; icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased expression of TGFB1 protein]]; icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased phosphorylation of MAPK8 protein]]; icatibant inhibits the reaction [KLK1 protein results in increased abundance of Nitric Oxide]
icatibant inhibits the reaction [KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] [icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of KNG1 protein]; icatibant inhibits the reaction [[KNG1 protein alternative form binds to and results in increased activity of BDKRB2 protein] which results in increased abundance of Inositol Phosphates]; icatibant inhibits the reaction [KNG1 protein inhibits the reaction [Potassium Chloride results in increased secretion of TAC1 protein]]; icatibant inhibits the reaction [KNG1 results in increased expression of PTGS2 mRNA]; icatibant inhibits the reaction [KNG1 results in increased secretion of TAC1 protein] icatibant results in decreased activity of KNG1 icatibant inhibits the reaction [KNG1 protein modified form binds to BDKRB2 protein]
icatibant inhibits the reaction [KNG1 protein inhibits the reaction [Potassium Chloride results in increased secretion of TAC1 protein]]; icatibant inhibits the reaction [KNG1 results in increased secretion of TAC1 protein]
[icatibant co-treated with Captopril] inhibits the reaction [bisphenol A results in increased expression of TGFB1 protein]; icatibant inhibits the reaction [KLK1 protein inhibits the reaction [Gentamicins results in increased expression of TGFB1 protein]]
browse the term
